

08-02-01

A
Box/seq

08/01/01



jc962 U.S. PTO


Certificate of Mailing

Date of Deposit August 1, 2001Label Number: EL790829755US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Guy Beardsley

Printed name of person mailing correspondence


 Signature of person mailing correspondence

jc972 U.S. PTO

09/20068



10/10/01

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. § 1.53(b)

Attorney Docket Number	50125/015002
Applicant	Eckhard Wolf et al.
Title	POLYPEPTIDES OR NUCLEIC ACIDS ENCODING THESE OF A FAMILY OF G-PROTEIN COUPLED RECEPTORS AND THEIR USE FOR THE DIAGNOSIS OR TREATMENT OF DISORDERS, FOR EXAMPLE SKIN DISORDERS AND THEIR USE FOR THE IDENTIFICATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES
PRIORITY INFORMATION:	
This application claims the benefit of the filing date of United States provisional patent application 60/229,501, filed August 31, 2000, and foreign patent application DE 10038111.1, filed August 4, 2000, in Germany.	
SMALL ENTITY STATUS:	
<input checked="" type="checkbox"/> Applicant claims small entity status under 37 C.F.R. § 1.27.	
APPLICATION ELEMENTS:	
Cover sheet	1 page
Specification	52 pages
Claims	6 pages
Abstract	1 page
Drawing	7 sheets
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	3 pages
Sequence Statement	2 pages
Sequence Listing on Paper	15 pages
Sequence Listing on Diskette	one disk

0920068-000101

☐ A copy from prior application [****SERIAL NUMBER****] and such small entity status is still proper and desired.

IDS

Cited References

English Translation

Return Receipt Postcard

1

Basic Filing Fee: \$355

\$355.00

Excess Claims Fee: 50 - 20 x \$9

\$270.00

Excess Independent Claims Fee: 5 - 3 x \$40

\$80.00

Multiple Dependent Claims Fee: \$135

\$135.00

Total Fees:

\$840.00

- Enclosed is a check for \$840.00 to cover the total fees.
- Please apply any other charges, or any credits, to Deposit Account No. 03-2095.

Karen L. Elbing, Ph.D.
Reg. No. 35,238
Clark & Elbing LLP
176 Federal Street
Boston, MA 02110

Telephone: 617-428-0200
Facsimile: 617-428-7045

CUSTOMER NO: 21559

Signature

1 August 2001


Date _____

\\Clark-w2k1\documents\50125\50125.015002 Utility Transmittal.wpd



21559

PATENT TRADEMARK OFFICE

Certificate of Mailing	
Date of Deposit <u>August 1, 2001</u>	Label Number: <u>EL790829755US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eckhard Wolf et al. Art Unit:
Serial No.: Not yet assigned Examiner:
Filed: August 1, 2001 Customer No.: 21559
Title: POLYPEPTIDES OR NUCLEIC ACIDS ENCODING THESE OF A
FAMILY OF G-PROTEIN COUPLED RECEPTORS AND THEIR USE
FOR THE DIAGNOSIS OR TREATMENT OF DISORDERS, FOR
EXAMPLE SKIN DISORDERS AND THEIR USE FOR THE
IDENTIFICATION OF PHARMACOLOGICALLY ACTIVE
SUBSTANCES

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 15 pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing.

And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.


As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 1 August 2001



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559
PATENT TRADEMARK OFFICE

09920068-030101